Eupraxia Doses First Patient In Phase 2B Placebo-Controlled Portion Of Ep-104GI Resolve Trial
View all comments(0)
July 8 (Reuters) - Eupraxia Pharmaceuticals Inc EPRX.TO:
EUPRAXIA DOSES FIRST PATIENT IN PHASE 2B PLACEBO-CONTROLLED PORTION OF EP-104GI RESOLVE TRIAL IN EOSINOPHILIC ESOPHAGITIS
EUPRAXIA PHARMACEUTICALS INC - TOPLINE DATA FROM PHASE 2B STUDY EXPECTED BY Q3 2026
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Like
Recommended Articles
Featured Tools
Top News
Why SanDisk Stock Could Soar to $4,000?

Is Micron the Next Nvidia? Why the 2026 "Memory Crunch" Makes MU Stock a Top AI Buy

AI Chip Sector Adds Heavyweight Player, Nvidia Rival Cerebras Plans to List Next Week, Targeting Largest US IPO of the Year

'Big Short' Burry Doubles Down: Nvidia, Palantir Short Positions Double in Big Bet on AI Bubble Bursting

Global First Storage ETF Surges 88% Five Weeks After Listing. Is It Too Late to Buy Now?

Tradingkey







Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.